CXCR7 antagonist-1

CAS No. 1613021-99-0

CXCR7 antagonist-1( —— )

Catalog No. M35092 CAS No. 1613021-99-0

CXCR7 antagonist-1 is a specific antagonist of the binding of the SDF-1 chemokine or I-TAC to the chemokine receptor CXCR7.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 286 Get Quote
5MG 454 Get Quote
10MG 655 Get Quote
25MG 994 Get Quote
50MG 1362 Get Quote
100MG 1764 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    CXCR7 antagonist-1
  • Note
    Research use only, not for human use.
  • Brief Description
    CXCR7 antagonist-1 is a specific antagonist of the binding of the SDF-1 chemokine or I-TAC to the chemokine receptor CXCR7.
  • Description
    CXCR7 antagonist-1 is a CXCR7 antagonist that inhibits the binding of the SDF-1 chemokine (also known as the CXCL12 chemokine) or I-TAC (also known as CXCL11) to the chemokine receptor CXCR7. CXCR7 antagonist-1 is useful in preventing tumor cell proliferation, tumor formation, inflammatory diseases, and many other diseases (extracted from patent WO2014085490A1, compound 1.128).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Autophagy
  • Target
    CXCR
  • Recptor
    CXCR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1613021-99-0
  • Formula Weight
    390.41
  • Molecular Formula
    C21H19FN6O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (256.14 mM; Ultrasonic )
  • SMILES
    Fc1ccc(cc1)-n1ccc(n1)C(=O)N[C@H]1CCN(C1)c1nccn2cccc12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Junfa Fan, et al. Cxcr7 antagonists. Patent WO2014085490A1.
molnova catalog
related products
  • FC131 TFA

    FC131 TFA (606968-52-9 free base) (FC131 TFA) is an antagonist of CXCR4 that inhibits the binding of [125I] -sdf-1 to CXCR4(IC50 : 4.5 nM ), and has anti-hiv activity.

  • Ulocuplumab

    Ulocuplumab (BMS-936564) is a fully human anti-CXCR4 IgG4 antibody.Ulocplumab exhibits antitumor activity in acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), and multiple myeloma transplantation models.

  • USL311

    USL311 is a CXCR4 receptor antagonist which prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4.?USL311 inhibits CXCR4 activation and decreases proliferation and migration of CXCR4-expressing tumor cells, with anti-tumor activity.